 Bragar Eagel Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased Lipocine, Inc. LPCN securities between March 27, 2019 and November 8, 2019 the Class Period. Lipocines lead product candidate is TLANDO LPCN 1021, an oral testosterone replacement therapy. The Company has previously submitted New Drug Applications NDA for TLANDO twice and, both times, received Complete Response Letters CRL from the U.S. Food and Drug Administration FDA rejecting the NDAs. 